Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DRUG Bright Minds Biosciences	$23.27 -6.1%	$29.56	$0.93 ▼ $79.02	$174.55M	-5.75	828,351 shs	627,261 shs
GYRE Gyre Therapeutics	$7.42 +0.5%	$9.06	$6.11 ▼ $19.00	$691.93M	1.79	130,821 shs	1.05 million shs
IMNM Immunome	$8.77 -0.2%	$8.61	$5.15 ▼ $16.81	$764.84M	1.94	900,000 shs	1.07 million shs
PHAT Phathom Pharmaceuticals	$9.74 +2.0%	$5.75	$2.21 ▼ $19.71	$666.72M	0.08	1.53 million shs	1.23 million shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DRUG Bright Minds Biosciences	-6.09%	-14.79%	-14.92%	-36.25%	+2,095.28%
GYRE Gyre Therapeutics	+0.54%	-8.05%	-21.40%	-18.55%	-20.73%
IMNM Immunome	-0.23%	+0.23%	+1.62%	+25.46%	-27.10%
PHAT Phathom Pharmaceuticals	+1.99%	-6.53%	+138.73%	+47.58%	-4.70%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DRUG Bright Minds Biosciences	3.115 of 5 stars	3.6	3.0	3.8	2.5	0.0
GYRE Gyre Therapeutics	0.2713 of 5 stars	0.0	2.0	2.5	0.8	0.0
IMNM Immunome	2.2169 of 5 stars	3.5	2.0	2.2	2.5	0.0
PHAT Phathom Pharmaceuticals	3.8374 of 5 stars	4.5	1.0	2.5	5.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DRUG Bright Minds Biosciences	3.25	Buy	$83.25	257.76% Upside
GYRE Gyre Therapeutics	3.00	Buy	N/A	N/A
IMNM Immunome	3.00	Buy	$23.33	166.06% Upside
PHAT Phathom Pharmaceuticals	3.00	Buy	$17.50	79.67% Upside

Current Analyst Ratings Breakdown

Latest DRUG, IMNM, GYRE, and PHAT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/9/2025	PHAT Phathom Pharmaceuticals	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$12.00 ➝ $17.00
6/9/2025	PHAT Phathom Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
6/6/2025	PHAT Phathom Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$28.00
5/21/2025	DRUG Bright Minds Biosciences	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00
5/13/2025	DRUG Bright Minds Biosciences	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
5/13/2025	DRUG Bright Minds Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/13/2025	DRUG Bright Minds Biosciences	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
5/13/2025	IMNM Immunome	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$33.00 ➝ $21.00
5/7/2025	DRUG Bright Minds Biosciences	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$80.00
5/2/2025	PHAT Phathom Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$10.00 ➝ $5.00
5/2/2025	PHAT Phathom Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$18.00 ➝ $12.00

(Data available from 6/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DRUG Bright Minds Biosciences	N/A	N/A	N/A	N/A	$0.92 per share	N/A
GYRE Gyre Therapeutics	$105.76M	6.58	$0.20 per share	37.37	$1.05 per share	7.07
IMNM Immunome	$9.04M	84.41	N/A	N/A	$2.27 per share	3.86
PHAT Phathom Pharmaceuticals	$55.25M	12.31	N/A	N/A	($3.71) per share	-2.63

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DRUG Bright Minds Biosciences	-$2.06M	-$0.36	N/A	N/A	N/A	N/A	-14.56%	-14.29%	8/13/2025 (Estimated)
GYRE Gyre Therapeutics	$12.09M	$0.02	371.19	∞	N/A	7.20%	9.73%	7.66%	8/12/2025 (Estimated)
IMNM Immunome	-$292.96M	-$3.18	N/A	N/A	N/A	-1,875.21%	-71.65%	-60.36%	8/11/2025 (Estimated)
PHAT Phathom Pharmaceuticals	-$334.33M	-$5.24	N/A	N/A	N/A	-422.42%	N/A	-90.11%	8/6/2025 (Estimated)

Latest DRUG, IMNM, GYRE, and PHAT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q2 2025	DRUG Bright Minds Biosciences	-$0.39	-$0.29	+$0.10	-$0.29	N/A	N/A
5/12/2025	Q1 2025	IMNM Immunome	-$0.66	-$0.52	+$0.14	-$0.52	$0.46 million	$2.93 million
5/9/2025	Q1 2025	GYRE Gyre Therapeutics	$0.03	$0.03	N/A	N/A	$28.40 million	$22.06 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DRUG Bright Minds Biosciences	N/A	N/A	N/A	N/A	N/A
GYRE Gyre Therapeutics	N/A	N/A	N/A	N/A	N/A
IMNM Immunome	N/A	N/A	N/A	N/A	N/A
PHAT Phathom Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DRUG Bright Minds Biosciences	N/A	126.01	126.01
GYRE Gyre Therapeutics	N/A	3.60	3.19
IMNM Immunome	N/A	10.49	10.49
PHAT Phathom Pharmaceuticals	N/A	3.58	3.54

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DRUG Bright Minds Biosciences	40.52%
GYRE Gyre Therapeutics	23.99%
IMNM Immunome	44.58%
PHAT Phathom Pharmaceuticals	99.01%

Insider Ownership

Company	Insider Ownership
DRUG Bright Minds Biosciences	42.66%
GYRE Gyre Therapeutics	10.00%
IMNM Immunome	8.60%
PHAT Phathom Pharmaceuticals	23.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DRUG Bright Minds Biosciences	N/A	7.04 million	4.04 million	Not Optionable
GYRE Gyre Therapeutics	40	93.76 million	84.38 million	No Data
IMNM Immunome	40	87.01 million	79.53 million	Optionable
PHAT Phathom Pharmaceuticals	110	69.81 million	53.76 million	Optionable

DRUG, IMNM, GYRE, and PHAT Headlines

Recent News About These Companies

Phathom Pharmaceuticals: Potential Blockbuster Gastric Acid-Reducing Drug With New Mechanism

June 25 at 5:07 AM | seekingalpha.com

Phathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary - Morningstar

June 24, 2025 | morningstar.comM

Phathom Pharmaceuticals, Inc. (PHAT) - Yahoo Finance

June 24, 2025 | finance.yahoo.com

Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 23, 2025 | globenewswire.com

Phathom Pharmaceuticals Appoints Cook as Chief Legal Officer

June 23, 2025 | news.bloomberglaw.comN

Phathom Pharmaceuticals (NASDAQ:PHAT) Trading Down 6.8% - Time to Sell?

June 23, 2025 | marketbeat.com

Phathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary

June 23, 2025 | globenewswire.com

Brokerages Set Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Target Price at $17.50

June 21, 2025 | americanbankingnews.com

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Given Average Rating of "Buy" by Brokerages

June 18, 2025 | marketbeat.com

Phathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Down 4.6% - Should You Sell?

June 16, 2025 | marketbeat.com

Phathom Pharmaceuticals Announces FDA Correction to Orange Book Listing, Confirming 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets Through May 3, 2032

June 16, 2025 | globenewswire.com

Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Gap Up - Should You Buy?

June 12, 2025 | marketbeat.com

Phathom Pharmaceuticals (NASDAQ:PHAT) Trading 6.4% Higher - Should You Buy?

June 11, 2025 | marketbeat.com

Tiny Phathom Pharmaceuticals Just An Got FDA Blessing And Big-Time Upside: Buy

June 10, 2025 | seekingalpha.com

Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Down 9.7% - Here's What Happened

June 9, 2025 | marketbeat.com

Phathom: Share Price Surge On Patent News May Not Stop The Rot For Long

June 9, 2025 | seekingalpha.com

Traders Purchase High Volume of Call Options on Phathom Pharmaceuticals (NASDAQ:PHAT)

June 9, 2025 | marketbeat.com

Phathom Pharmaceuticals (NASDAQ:PHAT) Given New $17.00 Price Target at Craig Hallum

June 9, 2025 | marketbeat.com

Wall Street Analysts Believe Phathom Pharmaceuticals (PHAT) Could Rally 107.4%: Here's is How to Trade

June 9, 2025 | zacks.com

Phathom Pharmaceuticals (NASDAQ:PHAT) Given "Buy" Rating at HC Wainwright

June 9, 2025 | marketbeat.com

Phathom Pharmaceuticals Announces Positive FDA Decision to Recognize 10 Years of Regulatory Exclusivity for VOQUEZNA (vonoprazan) Tablets through May 3, 2032

June 8, 2025 | finanznachrichten.de

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
With Novo Nordisk's CEO Out, Wall Street Wants an American Leader
By Leo Miller | June 7, 2025
View With Novo Nordisk's CEO Out, Wall Street Wants an American Leader
Analysts Can't Get Enough of These Little-Known Biopharma Stocks
By Nathan Reiff | June 12, 2025
View Analysts Can't Get Enough of These Little-Known Biopharma Stocks
Eli Lilly : A Breakout Biotech Powerhouse With Room to Run
By Jeffrey Neal Johnson | May 29, 2025
View Eli Lilly : A Breakout Biotech Powerhouse With Room to Run
IonQ’s $1B Acquisition and Drug Discovery Leap With NVIDIA
By Leo Miller | June 12, 2025
View IonQ’s $1B Acquisition and Drug Discovery Leap With NVIDIA

DRUG, IMNM, GYRE, and PHAT Company Descriptions

Bright Minds Biosciences NASDAQ:DRUG

$23.27 -1.51 (-6.09%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$24.39 +1.12 (+4.83%)

As of 06/27/2025 07:56 PM Eastern

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.

Gyre Therapeutics NASDAQ:GYRE

$7.42 +0.04 (+0.54%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$7.42 0.00 (0.00%)

As of 06/27/2025 06:08 PM Eastern

Gyre Therapeutics, Inc., a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.

Immunome NASDAQ:IMNM

$8.77 -0.02 (-0.23%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$8.72 -0.05 (-0.57%)

As of 06/27/2025 05:18 PM Eastern

Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

Phathom Pharmaceuticals NASDAQ:PHAT

$9.74 +0.19 (+1.99%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$9.66 -0.08 (-0.86%)

As of 06/27/2025 07:55 PM Eastern

Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time